The patients underwent computed tomography scan covering target lesions 4-6 weeks after the initiation of EGFR-TKIs treatment and then every 8 weeks or when indicated by symptoms. (N=150) who received EGFR-TKIs (gefitinib or erlotinib) as second- or third-line therapy from September 2008 to December 2012 were included in the study. In 66 NSCLC patients with … Continue reading The patients underwent computed tomography scan covering target lesions 4-6 weeks after the initiation of EGFR-TKIs treatment and then every 8 weeks or when indicated by symptoms